50
Participants
Start Date
April 14, 2025
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2026
RO7790121
Participants will be administered RO7790121 via IV infusion on Day 1, and Weeks 2, 6 and 10. Participants will then be administered RO7790121 SC injections every four weeks (Q4W) from week 14 up to and including Week 50.
Inovacion y Desarrollo en ciencias de la salud, Ciudad de Mxico
CIMAB S.A. de C.V., Torreón
Gastrointestinal Specialists of Georgia, PC, Marietta
Mediadvance Clinical SAPI De CV, Chihuahua City
Gastro Health Research - Miami, Miami
Premier Medical Group Int Medcn, Clarksville
Gastroenterology Center of the MidSouth PC, Cordova
Centro de Investigacion Clinica y Medicina Traslacional CIMeT, Guadalajara
Hospital General de Occidente SSJ, Zapopan
Clínica de Enfermedades Crónicas y de Procedimientos Especiales, S.C (CECYPE), Morelia
Centro Médico Zambrano Hellion, San Pedro Garza García
Delta Research Partners, LLC (Bastrop), Bastrop
GI Alliance, Southlake
Houston Research Institute, Houston
Bellaire Clinical Research, LLC, Bellaire
Pinnacle Clinical Research, PLLC, San Antonio
DHR Health Institute for Research and Development, Edinburg
Pinnacle Clinical Research Georgetown, Georgetown
Pinnacle Clinical Research - Austin, Austin
Adobe Clinical Research, LLC, Tucson
Jubilee Clinical Research, Inc, Las Vegas
GI Alliance, Bellevue
Centro de Investigacion y Gastroenterologia, Mexico City
FDI Clinicial Research - Mayaguez, Mayagez
Fundacion de Investigacion de Diego, San Juan
Hoffmann-La Roche
INDUSTRY